Antisense Libraries to Isolate Tumor Suppressor Genes

  • Adi Kimchi
Part of the Methods in Molecular Biology™ book series (MIMB, volume 222)

Abstract

Apoptosis has become a subject that draws tremendous attention and research efforts in the cancer field, since it has a major impact on tumor initiation, progression, and metastasis. At various stages during the course of tumor development, cells are subjected to stressful conditions that trigger different types of programmed cell death, including the classic type of apoptosis. As a consequence, mutations leading to inhibition of apoptosis confer a selective advantage to cells. In premalignant cells, activation of oncogenes and the consequent hyperproliferation provoke a cellular response that leads to elimination of those cells by apoptosis. Subsequently, transformed cells in the tumor microenvironment are under constant selective death pressure, due to lack of oxygen (hypoxia), depletion of growth/survival factors, attacks by the immune system and often death by anoikis that results from loss of cell-matrix interactions. At later stages, when metastasizing tumor cells enter into circulation, they encounter many additional death-inducing signals, such as superoxides, nitric oxide (NO), killing cytokines, and mechanical shearing forces. Thus, all along the multistage process of tumorigenesis, induction of apoptosis functions as a tumor suppressor mechanism from which cells have to escape in order to survive (reviewed in refs. 1, 2, 3). This means that tumor cells should benefit from mutations that either inactivate proteins that positively mediate programmed cell death (PCD) or alternatively abnormally activate antiapoptotic genes.

Keywords

Lymphoma Superoxide Fractionation Interferon Myeloma 

References

  1. 1.
    Kaufmann, S. H. and Gores, G. J. (2000) Apoptosis in cancer: cause and cure. Bioessays 22, 1007–1017.PubMedCrossRefGoogle Scholar
  2. 2.
    Lowe, S. W. and Lin, A. W. (2000) Apoptosis in cancer. Carcinogenesis 21, 485–495.PubMedCrossRefGoogle Scholar
  3. 3.
    Wyllie, A. H., Bellamy, C. O., Bubb, V. J., et al. (1999) Apoptosis and carcinogenesis. Br. J. Cancer, 80Suppl 1, 34–37.PubMedGoogle Scholar
  4. 4.
    McDonnell, T. J., Deane, N., Platt, et al. (1989) bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57, 79–88.PubMedCrossRefGoogle Scholar
  5. 5.
    Strasser, A., Harris, A. W., Vaux, D. L., et al. (1990) Abnormalities of the immune system induced by dysregulated bcl-2 expression in transgenic mice. Curr. Top. Microbiol. Immunol. 166, 175–181.PubMedCrossRefGoogle Scholar
  6. 6.
    Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A. and Oren, M. (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352, 345–347PubMedCrossRefGoogle Scholar
  7. 7.
    Gottlieb, T. M. and Oren, M. (1998) p53 and apoptosis. Semin. Cancer Biol. 8, 359–368.PubMedCrossRefGoogle Scholar
  8. 8.
    Horvitz, H. R. (1999) Genetic control of programmed cell death in the nematode Caenorhabditis elegans. Cancer Res. 59, 1701s–1706s.PubMedGoogle Scholar
  9. 9.
    Steller, H. (1995) Mechanisms and genes of cellular suicide. Science 267, 1445–1449.PubMedCrossRefGoogle Scholar
  10. 10.
    Deiss, L. P. and Kimchi, A. (1991) A genetic tool used to identify thioredoxin as a mediator of a growth inhibitory signal. Science 252, 117–120.PubMedCrossRefGoogle Scholar
  11. 11.
    Kimchi, A. (1998) DAP genes: novel apoptotic genes isolated by a functional approach to gene cloning. Biochim. Biophys. Acta 1377, F13–F33.PubMedGoogle Scholar
  12. 12.
    Kissil, J. L. and Kimchi, A. (1998) Death-associated proteins: from gene identification to the analysis of their apoptotic and tumour suppressive functions. Mol. Med. Today 4, 268–274.PubMedCrossRefGoogle Scholar
  13. 13.
    Deiss, L. P., Feinstein, E., Berissi, H., Cohen, O., and Kimchi, A. (1995) Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev. 9, 15–30.PubMedCrossRefGoogle Scholar
  14. 14.
    Cohen, O., Feinstein, E., and Kimchi, A. (1997) DAP-kinase is a Ca2+/calmodulin-dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. EMBO J. 16, 998–1008.PubMedCrossRefGoogle Scholar
  15. 15.
    Cohen, O., Inbal, B., Kissil, J. L., et al. (1999) DAP-kinase participates in TNF-alpha-and Fas-induced apoptosis and its function requires the death domain. J. Cell Biol. 146, 141–148.PubMedGoogle Scholar
  16. 16.
    Kissil, J. L., Deiss, L., Bayewitch, M., Raveh, T., Khaspekov, G., and Kimchi, A. (1995) Isolation of DAP3, a novel mediator of interferon-gamma-induced cell death. J. Biol. Chem. 270, 27932–27936.PubMedCrossRefGoogle Scholar
  17. 17.
    Kissil, J. L., Cohen, O., Raveh, T. and Kimchi, A. (1999) Structure–function analysis of an evolutionary conserved protein, DAP3, which mediates TNF-alpha-and Fas-induced cell death. EMBO J. 18, 353–362.PubMedCrossRefGoogle Scholar
  18. 18.
    Levy Strumpf, N., Deiss, L. P., Berissi, H., and Kimchi, A. (1997) DAP-5, a novel homolog of eukaryotic translation initiation factor 4G isolated as a putative modulator of gamma interferon-induced programmed cell death. Mol. Cell. Biol. 17, 1615–1625.Google Scholar
  19. 19.
    Henis-Korenblit, S., Strumpf, N. L., Goldstaub, D., and Kimchi, A. (2000) A novel form of DAP5 protein accumulates in apoptotic cells as a result of caspase cleavage and internal ribosome entry site-mediated translation. Mol. Cell Biol. 20, 496–506.PubMedCrossRefGoogle Scholar
  20. 20.
    Feinstein, E., Wallach, D., Boldin, M., Varfolomeev, E., and Kimchi, A. (1995) The death domain: a module shared by proteins with diverse cellular functions. Trends. Biochem. Sci. 20, 342–344.PubMedCrossRefGoogle Scholar
  21. 21.
    Inbal, B., Cohen, O., Polak-Charcon, S., et al. (1997) DAP kinase links the control of apoptosis to metastasis. Nature 390, 180–184.PubMedCrossRefGoogle Scholar
  22. 22.
    Raveh, T., Droguett, G., Horwitz, M. S., DePinho, R. A., and Kimchi, A. (2001) DAP-kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat. Cell Biol. 3, 1–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Inbal, B., Shani, G., Cohen, O., Kissil, J. L., and Kimchi, A. (2000) Death-associated protein kinase-related protein 1, a novel serine/threonine kinase involved in apoptosis. Mol. Cell Biol. 20, 1044–1054.PubMedCrossRefGoogle Scholar
  24. 24.
    Kogel, D., Prehn, J. H. and Scheidtmann, K. H. (2001) The DAP kinase family of pro-apoptotic proteins: novel players in the apoptotic game. Bioessays 23, 352–358.PubMedCrossRefGoogle Scholar
  25. 25.
    Lowe, S. W. (1999) Activation of p53 by oncogenes [In Process Citation]. Endocr. Relat. Cancer 6, 45–48.PubMedCrossRefGoogle Scholar
  26. 26.
    Sherr, C. J. (1998) Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12, 2984–2991.PubMedCrossRefGoogle Scholar
  27. 27.
    Kissil, J. L., Feinstein, E., Cohen, O., et al. (1997) DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene. Oncogene 15, 403–407.PubMedCrossRefGoogle Scholar
  28. 28.
    Katzenellenbogen, R. A., Baylin, S. B., and Herman, J. G. (1999) Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 93, 4347–4353.PubMedGoogle Scholar
  29. 29.
    Nakatsuka, S., Takakuwa, T., Tomita, Y., Miwa, H., Matsuzuka, F., and Aozasa, K. (2000) Role of hypermethylation of DAP-kinase CpG island in the development of thyroid lymphoma. Lab. Invest. 80, 1651–1655.PubMedCrossRefGoogle Scholar
  30. 30.
    Esteller, M., Sanchez-Cespedes, M., Rosell, R., Sidransky, D., Baylin, S. B., and Herman, J. G. (1999) Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59, 67–70.PubMedGoogle Scholar
  31. 31.
    Tang, X., Khuri, F. R., Lee, J. J., et al. (2000) Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J. Natl. Cancer Inst. 92, 1511–1516.PubMedCrossRefGoogle Scholar
  32. 32.
    Kim, D. H., Nelson, H. H., Wiencke, J. K., et al. (2001) Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene 20, 1765–1770.PubMedCrossRefGoogle Scholar
  33. 33.
    Sanchez-Cespedes, M., Esteller, M., Wu, L., et al. (2000) Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 60, 892–895.PubMedGoogle Scholar
  34. 34.
    Rosas, S. L., Koch, W., da Costa Carvalho, M. G., et al. (2001) Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 61, 939–942.PubMedGoogle Scholar
  35. 35.
    Ng, M. H., To, K. W., Lo, K. W., et al. (2001) Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma. Clin. Cancer Res. 7, 1724–1729.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2003

Authors and Affiliations

  • Adi Kimchi
    • 1
  1. 1.Department of Molecular Genetics and Virologythe Weizmann Institute of ScienceRehovotIsrael

Personalised recommendations